dc.contributor.author | Plummer, FA | |
dc.contributor.author | Maggwa, N | |
dc.contributor.author | D'Costa, LJ | |
dc.contributor.author | Nsanze, H | |
dc.contributor.author | Karasira, P | |
dc.contributor.author | Maclean, IW | |
dc.contributor.author | Ronald, AR | |
dc.date.accessioned | 2013-06-11T08:16:12Z | |
dc.date.available | 2013-06-11T08:16:12Z | |
dc.date.issued | 1984-12 | |
dc.identifier.citation | Sex Transm Dis. 1984 Oct-Dec;11(4):304-7. | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/6098034 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/31234 | |
dc.description.abstract | The authors conducted a double-blind randomized clinical trial comparing single-dose cefotaxime (1 g im) plus daily placebo injections with cefotaxime (1 g im on each of three days). Each regimen was given with probenicid (1 g orally) for the treatment of chancroid. Twenty Haemophilus ducreyi culture-positive men received the single-dose cefotaxime regimen; in eight patients ulcers or buboes failed to respond to therapy. Nineteen H. ducreyi culture-positive men received cefotaxime on each of three days; H. ducreyi was eradicated from all patients, but one had a continuing ulcer and another had a bubo that failed to respond. Thus cefotaxime (1 g im daily for three days) plus probenicid (1 g orally) is effective therapy for chancroid. The lack of efficacy for chancroid of the single-dose cefotaxime regimen is surprising, given the remarkable susceptibility of H. ducreyi to cefotaxime; presumably the half-life of cefotaxime is too short for predictable eradication of H. ducreyi from the ulcer with a single-dose regimen. | en |
dc.language.iso | en | en |
dc.publisher | University of Nairobi, | en |
dc.title | Cefotaxime treatment of Haemophilus ducreyi infection in Kenya. | en |
dc.type | Article | en |
local.publisher | Department of Medicine | en |